TLDR: The global Generative AI in Life Sciences market is projected to surge from USD 250 million in 2024 to an estimated USD 1,657.02 million by 2034, exhibiting a robust Compound Annual Growth Rate (CAGR) of 20.82% from 2025 to 2034. This expansion is primarily fueled by advancements in AI models accelerating drug discovery, clinical trial optimization, and personalized medicine.
Ottawa, September 30, 2025 – A new study published by Towards Healthcare, a sister firm of Precedence Research, reveals a significant growth trajectory for the global Generative AI (GenAI) in Life Sciences market. The market, valued at USD 250 million in 2024, is anticipated to reach approximately USD 1,657.02 million by 2034, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 20.82% between 2025 and 2034. The market was estimated at USD 302.05 million in 2025.
This substantial growth is attributed to groundbreaking advancements in AI models that are revolutionizing the design of novel molecules, proteins, and clinical trial strategies. These innovations are dramatically enhancing research productivity and significantly reducing costs across the life sciences sector. The increasing demand for personalized medicine, the imperative to accelerate drug development processes, and the seamless integration of AI with cutting-edge technologies for laboratory digitalization are key drivers propelling this market forward.
Key Market Insights:
Market Valuation: The Generative AI in Life Sciences market is expected to exceed USD 250 million in 2024 and is projected to hit USD 1,657.02 million by 2034.
Growth Rate: A CAGR of 20.82% is anticipated from 2025 to 2034.
Regional Dominance: North America held the largest revenue share in 2024, accounting for 42% of the market. This dominance is supported by substantial investments from both private and public sectors in AI and R&D, coupled with a favorable regulatory environment that fosters innovation.
Fastest-Growing Region: Asia Pacific is forecasted to be the fastest-growing region during the 2025-2034 period. This growth is driven by the increasing adoption of GenAI in clinical trials to enhance processes like trial design, patient selection, and data management, as well as its application in personalized healthcare solutions for analyzing vast datasets to tailor treatments.
Technological and Application Segments:
Technology: The novel molecule generation segment led the market in 2024, showcasing the immediate impact of GenAI in creating new therapeutic compounds. The protein sequence design segment is also expected to experience significant growth in the coming years.
Application: Drug discovery dominated the market in 2024, capturing the largest revenue share. The clinical trial segment is projected to exhibit the fastest CAGR over the forecast period, highlighting GenAI’s transformative potential in optimizing trial processes.
Also Read:
- Generative AI Poised for Explosive Growth in Agriculture, Market to Exceed $2 Billion by 2033
- Generative AI in Automotive Market Set for Rapid Expansion, Reaching $4.58 Billion by 2034
Generative AI tools, including generative adversarial networks (GANs), variational autoencoders (VAEs), and transformer-based models, are designed to create new biological entities and generate datasets crucial for therapeutic, diagnostic, and operational advancements. These tools are set to continue their profound transformation of research and development in biopharma, diagnostics, and biotech industries.
